Long-term safety and efficacy of emtricitabine and tenofovir alafenamide vs emtricitabine and tenofovir disoproxil fumarate for HIV-1 pre-exposure prophylaxis: week 96 results from a randomised, double-blind, placebo-controlled, phase 3 trialOnyema Ogbuagu, Jason Flamm, Peter Ruane et al.|The Lancet HIV|2021Cited by 91
Week 48 Resistance Analyses of the Once-Daily, Single-Tablet Regimen Darunavir/Cobicistat/Emtricitabine/Tenofovir Alafenamide (D/C/F/TAF) in Adults Living with HIV-1 from the Phase III Randomized AMBER and EMERALD TrialsErkki Lathouwers, Renato Maserati, Eric Wong et al.|AIDS Research and Human Retroviruses|2019Cited by 14
Time to virologic failure for patients taking their first antiretroviral regimen and the subsequent resistance profilesFrederic Crouzat, Mona Loutfy, Barry Merkley et al.|Journal of the International AIDS Society|2014Cited by 1
Time to Viremia for Patients Taking their First Antiretroviral Regimen and the Subsequent Resistance ProfilesFrederic Crouzat, Mona Loutfy, Anita C. Benoit et al.|HIV Clinical Trials|2016Cited by 0